816 related articles for article (PubMed ID: 30572906)
21. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
[TBL] [Abstract][Full Text] [Related]
22. Effectiveness and safety of hydroxychloroquine therapy with or without corticosteroid in patients with systemic lupus erythematosus.
Miyagawa I; Nakano K; Nakayamada S; Iwata S; Hanami K; Fukuyo S; Kubo S; Inoue Y; Ueno M; Tanaka Y
Int J Rheum Dis; 2019 Mar; 22(3):434-442. PubMed ID: 30338639
[TBL] [Abstract][Full Text] [Related]
23. Efficacy analysis of hydroxychloroquine therapy in systemic lupus erythematosus: a study on disease activity and immunological biomarkers.
Monzavi SM; Alirezaei A; Shariati-Sarabi Z; Tavakol Afshari J; Mahmoudi M; Dormanesh B; Jahandoost F; Khoshdel AR; Etemad Rezaie A
Inflammopharmacology; 2018 Oct; 26(5):1175-1182. PubMed ID: 29987550
[TBL] [Abstract][Full Text] [Related]
24. Clinical and immunological characteristics of 150 systemic lupus erythematosus patients in Jamaica: a comparative analysis.
Maloney KC; Ferguson TS; Stewart HD; Myers AA; De Ceulaer K
Lupus; 2017 Nov; 26(13):1448-1456. PubMed ID: 28480787
[TBL] [Abstract][Full Text] [Related]
25. Dysregulation of innate and adaptive serum mediators precedes systemic lupus erythematosus classification and improves prognostic accuracy of autoantibodies.
Lu R; Munroe ME; Guthridge JM; Bean KM; Fife DA; Chen H; Slight-Webb SR; Keith MP; Harley JB; James JA
J Autoimmun; 2016 Nov; 74():182-193. PubMed ID: 27338520
[TBL] [Abstract][Full Text] [Related]
26. Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies.
Khellaf M; Chabrol A; Mahevas M; Roudot-Thoraval F; Limal N; Languille L; Bierling P; Michel M; Godeau B
Am J Hematol; 2014 Feb; 89(2):194-8. PubMed ID: 24254965
[TBL] [Abstract][Full Text] [Related]
27. Validation of the Systemic Lupus International Collaborating Clinics classification criteria in a cohort of patients with full house glomerular deposits.
Rijnink EC; Teng YKO; Kraaij T; Dekkers OM; Bruijn JA; Bajema IM
Kidney Int; 2018 Jan; 93(1):214-220. PubMed ID: 28950993
[TBL] [Abstract][Full Text] [Related]
28. Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study.
Levy RA; Vilela VS; Cataldo MJ; Ramos RC; Duarte JL; Tura BR; Albuquerque EM; Jesús NR
Lupus; 2001; 10(6):401-4. PubMed ID: 11434574
[TBL] [Abstract][Full Text] [Related]
29. Long-term evaluation of antimalarials in a Dutch SLE cohort: intolerance and other reasons for non-use.
Tsang-A-Sjoe MW; Bultink IE; Voskuyl AE
Clin Exp Rheumatol; 2014; 32(1):95-100. PubMed ID: 24238093
[TBL] [Abstract][Full Text] [Related]
30. Longitudinal Treatment Patterns and Associated Outcomes in Patients With Newly Diagnosed Systemic Lupus Erythematosus.
Kan H; Nagar S; Patel J; Wallace DJ; Molta C; Chang DJ
Clin Ther; 2016 Mar; 38(3):610-24. PubMed ID: 26907503
[TBL] [Abstract][Full Text] [Related]
31. Flares after hydroxychloroquine reduction or discontinuation: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort.
Almeida-Brasil CC; Hanly JG; Urowitz M; Clarke AE; Ruiz-Irastorza G; Gordon C; Ramsey-Goldman R; Petri M; Ginzler EM; Wallace DJ; Bae SC; Romero-Diaz J; Dooley MA; Peschken C; Isenberg D; Rahman A; Manzi S; Jacobsen S; Lim S; van Vollenhoven RF; Nived O; Jönsen A; Kamen DL; Aranow C; Sanchez-Guerrero J; Gladman DD; Fortin PR; Alarcón GS; Merrill JT; Kalunian K; Ramos-Casals M; Steinsson K; Zoma A; Askanase A; Khamashta MA; Bruce IN; Inanc M; Abrahamowicz M; Bernatsky S
Ann Rheum Dis; 2022 Mar; 81(3):370-378. PubMed ID: 34911705
[TBL] [Abstract][Full Text] [Related]
32. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study.
Furie RA; Leon G; Thomas M; Petri MA; Chu AD; Hislop C; Martin RS; Scheinberg MA;
Ann Rheum Dis; 2015 Sep; 74(9):1667-75. PubMed ID: 24748629
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial).
Isenberg D; Gordon C; Licu D; Copt S; Rossi CP; Wofsy D
Ann Rheum Dis; 2015 Nov; 74(11):2006-15. PubMed ID: 24951103
[TBL] [Abstract][Full Text] [Related]
34. The efficacy of antimalarials in systemic lupus erythematosus.
Nayak V; Esdaile JM
Lupus; 1996 Jun; 5 Suppl 1():S23-7. PubMed ID: 8803906
[TBL] [Abstract][Full Text] [Related]
35. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
Kalunian KC; Merrill JT; Maciuca R; McBride JM; Townsend MJ; Wei X; Davis JC; Kennedy WP
Ann Rheum Dis; 2016 Jan; 75(1):196-202. PubMed ID: 26038091
[TBL] [Abstract][Full Text] [Related]
36. Vitamin D Supplementation in Adolescents and Young Adults With Juvenile Systemic Lupus Erythematosus for Improvement in Disease Activity and Fatigue Scores: A Randomized, Double-Blind, Placebo-Controlled Trial.
Lima GL; Paupitz J; Aikawa NE; Takayama L; Bonfa E; Pereira RM
Arthritis Care Res (Hoboken); 2016 Jan; 68(1):91-8. PubMed ID: 25988278
[TBL] [Abstract][Full Text] [Related]
37. Preclinical systemic lupus erythematosus.
Robertson JM; James JA
Rheum Dis Clin North Am; 2014 Nov; 40(4):621-35. PubMed ID: 25437281
[TBL] [Abstract][Full Text] [Related]
38. Systemic lupus Erythematosus activity and Hydroxychloroquine use before and after end-stage renal disease.
Salgado Guerrero M; Londono Jimenez A; Dobrowolski C; Mowrey WB; Goilav B; Wang S; Broder A
BMC Nephrol; 2020 Oct; 21(1):450. PubMed ID: 33115441
[TBL] [Abstract][Full Text] [Related]
39. Chloroquine, Hydroxychloroquine and Hearing Loss: A Study in Systemic Lupus Erythematosus Patients.
Polanski JF; Tanaka EA; Barros H; Chuchene AG; Miguel PTG; Skare TL
Laryngoscope; 2021 Mar; 131(3):E957-E960. PubMed ID: 32603516
[TBL] [Abstract][Full Text] [Related]
40. Diagnosis and risk stratification in patients with anti-RNP autoimmunity.
Carpintero MF; Martinez L; Fernandez I; Romero AC; Mejia C; Zang YJ; Hoffman RW; Greidinger EL
Lupus; 2015 Sep; 24(10):1057-66. PubMed ID: 25736140
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
